#USA #San Diego #Lung Cancer #Geminii #Bioelectronic Therapy

Geminii to Exhibit New Lung Cancer Data at AACR 2026

Geminii, Inc., a pioneering entity in the field of bioelectronic medicine, has announced an exciting new development as it prepares to showcase its latest research at the upcoming AACR Annual Meeting 2026 in San Diego. The presentation will focus on their breakthrough bioelectronic therapy targeting non-small cell lung cancer (NSCLC), a prevalent and often aggressive type of lung cancer.

The poster presentation, titled "Bioelectromagnetic Reprogramming of Tumor-Immune Metabolism to Selectively Destroy NSCLC," is scheduled for April 22, 2026. Significant findings from the studies indicate that Geminii's innovative therapy not only slowed tumor growth but also extended survival rates in preclinical models. Moreover, it demonstrated an ability to enhance the effectiveness of chemoradiation without causing toxicity to healthy tissues.

Innovative Approach with Promising Results

The research findings highlight an intricate relationship between bioelectronic therapy and the modulation of tumor-immune metabolism. Data suggests that the therapy increased markers indicative of tumor-cell damage and showcased enhanced immune activation within the tumor microenvironment. These results are particularly groundbreaking as they provide evidence of a differentiated approach to treating NSCLC, which has long posed challenges in oncology.

Calvin Carter, CEO of Geminii and Ph.D., expressed enthusiasm regarding the potential implications of their research. "These findings are exciting not only because they highlight a differentiated approach in NSCLC, but also because they suggest our platform may extend beyond metabolic disease into oncology. We believe this work supports the broader potential of bioelectronic medicine and may help open a new avenue for at-home, sleep-compatible cancer therapy."

Home-Based Treatment Revolution

The implications of this therapy could revolutionize conventional cancer treatment methodologies. Geminii is striving to not only complement existing cancer treatment regimes but also provide patients with a non-invasive option suitable for at-home use. This could mean that patients may be able to receive effective cancer treatments while they sleep, which could be a game-changer for patient quality of life and adherence to therapy.

The poster presentation at AACR 2026 promises to delve into the specifics of the findings, including detailed information about the study's design and the nature of the bioelectronic interventions used. Researchers, clinicians, and attendees interested in the field of oncology will likely benefit immensely from this innovative research.

Those who wish to learn more can visit the AACR Annual Meeting's official website, where additional details about the abstract and poster presentation can be found. As cancer remains one of the leading health challenges today, advancements such as those reported by Geminii appear to be steps toward more effective and patient-friendly treatment options.

Conclusion

With the presentation of this new lung cancer data, Geminii is positioning itself at the forefront of a potential shift in oncological care, advocating for innovative therapeutic approaches that not only treat but also empower patients in their fight against cancer. The upcoming AACR Annual Meeting presents a crucial platform for these findings, which hold the promise of advancing cancer treatment far beyond the current standards.

For more information, stay tuned to Geminii's official updates as they continue to develop their bioelectronic medicine platform, promising not just hope, but tangible breakthroughs in the realm of oncology.